NTHU
18.3.2020 10:02:08 CET | Business Wire | Press release
An NTHU interdisciplinary research team led by Associate Professor Wu Shan-hung of the Department of Computer Science, Associate Professor Liu Yi-wen of the Department of Electrical Engineering, and Chair Professor Chang Cheng-shang of the Institute of Communications Engineering has recently developed an automated system for the production of digital advertisements. Based on the information provided by the user, the system generates a variety of images and music, which can be fine-tuned to create the final product, thereby greatly reducing the time and cost of producing an advertisement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005022/en/
Wu and Chang designed a conditional generative adversarial network (CGAN) application which generates an ad based on a large amount of related information harvested from the internet by using artificial intelligence (AI). Afterwards, all that remains to be done is to have an advertising specialist edit the ad and add the finishing touches.
Wu explained that the application performs a social network analysis which determines the most popular elements and user preferences to generate eye-catching digital advertisements and optimal screen layouts. For example, the user enters a photo of a bed set with a circle around the bed, and the system automatically generates a variety of ads highlighting the bed’s unique characteristics.
The application can also generate advertisements with models. For example, the user enters a photo of Keanu Reeves after circling certain features he wants to keep, such as the forehead and eyes, and the system will incorporate these features into a new image with similar characteristics.
Wu's team worked with the startup AppFinca to redesign the webpage for its app called “Flora.” After analysis, the team changed Flora's advertising slogan to “He grows trees, and you grow up,” and also came up with a lively color scheme to replace the rather drab one originally used for the page.
The transformation resulted in Flora shooting up to the top position in the rankings of the Free Productivity Tools of the Apple App Store for Taiwan, outranking even Gmail. AppFinca vice president Sun Zhen-wei said that the cost was only 60% of the original advertising fee.
The application developed by the research team also produces jingles. They collected 600 songs and used them to train the system to generate a jingle based on the lyrics and melody, and the result can be adjusted in terms of pitch, timbre, and rhythm. Even though the jingles generated by the application aren’t likely to be nominated for a Grammy Award, the system significantly speeds up the creative process.
The research team has already published a total of 19 articles on their research, and have also presented their results at various international conferences, including the Conference on Neural Information Processing Systems and the International Conference on Acoustics, Speech, and Signal Processing. They are also conducting negotiations with United Microelectronics, Asus, for commercial application of their system.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005022/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
